ADC Therapeutics SA
NYSE:ADCT

Watchlist Manager
ADC Therapeutics SA Logo
ADC Therapeutics SA
NYSE:ADCT
Watchlist
Price: 3.5 USD -5.41% Market Closed
Market Cap: 433.6m USD

ADC Therapeutics SA
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

ADC Therapeutics SA
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
ADC Therapeutics SA
NYSE:ADCT
Cash from Operating Activities
-$131.9m
CAGR 3-Years
3%
CAGR 5-Years
3%
CAGR 10-Years
N/A
AC Immune SA
NASDAQ:ACIU
Cash from Operating Activities
-CHf46.8m
CAGR 3-Years
14%
CAGR 5-Years
2%
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Cash from Operating Activities
-$302.5m
CAGR 3-Years
14%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Cash from Operating Activities
CHf79.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Idorsia Ltd
SIX:IDIA
Cash from Operating Activities
-CHf120.9m
CAGR 3-Years
48%
CAGR 5-Years
20%
CAGR 10-Years
N/A
Kuros Biosciences AG
SIX:KURN
Cash from Operating Activities
CHf1.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

ADC Therapeutics SA
Glance View

Market Cap
394.2m USD
Industry
Biotechnology

ADC Therapeutics SA is a clinical-stage biotechnology company. The company is headquartered in Epalinges, Vaud and currently employs 312 full-time employees. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.

ADCT Intrinsic Value
4.55 USD
Undervaluation 23%
Intrinsic Value
Price

See Also

What is ADC Therapeutics SA's Cash from Operating Activities?
Cash from Operating Activities
-131.9m USD

Based on the financial report for Sep 30, 2025, ADC Therapeutics SA's Cash from Operating Activities amounts to -131.9m USD.

What is ADC Therapeutics SA's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
3%

Over the last year, the Cash from Operating Activities growth was 2%. The average annual Cash from Operating Activities growth rates for ADC Therapeutics SA have been 3% over the past three years , 3% over the past five years .

Back to Top